eXoZymes (EXOZ) vs ImageneBio (IMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ImageneBio (IMA) has outperformed eXoZymes (EXOZ) over the past year, losing 44.7% versus a loss of 59.0%. ImageneBio is the larger company by market cap ($52.4 million vs $51.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EXOZ | IMA |
|---|---|---|
| Share price | $5.54 | $4.61 |
| Market cap | $51.55M | $52.43M |
| 1-day change | -3.15% | -1.91% |
| YTD return | -49.17% | -33.19% |
| 1-year return | -58.96% | -44.72% |
| 5-year return | — | -96.83% |
| EPS (TTM) | $-1.19 | $-4.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.40 | $9.10 |
| 52-week low | $4.35 | $3.94 |
| Distance from 52-week high | -69.89% | -49.34% |
| Average volume | 6.79K | 12.98K |
| Shares outstanding | 9.30M | 11.37M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMA has outperformed EXOZ by 14.2 percentage points over the past year.
EXOZ vs IMA FAQ
Which is bigger, eXoZymes or ImageneBio?
ImageneBio (IMA) is larger, with a market capitalization of $52.43M compared with $51.55M for eXoZymes (EXOZ).
Which stock has performed better over the past year, EXOZ or IMA?
IMA returned -44.72% over the past 12 months, compared with -58.96% for EXOZ (price return, excluding dividends). Past performance does not predict future results.
Are eXoZymes and ImageneBio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.